Low-order assemblies drive oncogenic RTK fusion signaling without condensation
David Gonzalez-MartineziD, Thomas R. MumfordiD, Delaney WildeiD, Sofia Wissert, Yuzhi (Carol) Gao, Emily Brackhahn, Richard Kriwacki, Elizabeth Rhoades, Lukasz J. BugajiD
Abstract
Receptor tyrosine kinase (RTK) fusions are a large class of oncoproteins found in [~]5% of cancers. Key questions remain, however, about how RTK fusions transmit oncogenic signals, including how these largely cytoplasmic proteins activate downstream pathways that originate at the plasma membrane. Fusions are multimeric and can form mesoscale condensates in cancer cells, and condensation has been implicated as an essential mechanism to enable signal transmission from the cytoplasm. However, whether condensates play a causal role, or whether smaller diffuse assemblies are sufficient to transduce signals, has been challenging to establish. Here we apply advanced microscopy, single-cell analysis, and synthetic fusions to determine the principles by which multimerization and condensation drive signaling from cytoplasmic RTK fusions. For EML4-ALK, a prominent fusion that forms condensates, we found poor correlation between condensation and signaling. By contrast, EML4-ALK activity was abundant in the diffuse phase, and the kinetics of diffuse-phase activity aligned more closely with downstream Erk signaling than did kinetics of signaling within condensates. Synthetic RTK fusions showed that cytoplasmic ALK or RET fusion dimers--and even constitutively active monomers--were sufficient to induce strong Ras-Erk signaling despite the absence of condensates, and diffuse fusions were sufficient to transform cells in vitro and in subcutaneous tumor models. A panel of various other cancer-driving RTK fusions showed that low-order multimerization was universal across fusions, whereas mesoscale condensation was rare and did not correlate with signaling. Our results suggest that low-order fusion multimerization is sufficient to drive its phosphorylation, which is necessary and sufficient to trigger downstream oncogenic signaling.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- EGFR suppression and drug-induced potentiation are widespread features of oncogenic RTK fusions
Yuzhi Gao, David Gonzalez-Martinez, … Lukasz J. Bugaj·bioRxiv·Nov 19, 2025
- Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules
A. Tulpule, J. Guan, … T. G. Bivona·bioRxiv·Apr 9, 2020
- Oncogenic protein condensates suppress growth factor perception and modulate drug tolerance
D. Gonzalez-Martinez, L. Roth, … L. J. Bugaj·bioRxiv·Feb 2, 2022
- Receptor tyrosine kinases regulate signal transduction through a liquid-liquid phase separated state
C.-C. Lin, K. M. Suen, … J. E. Ladbury·Molecular CellPeer-reviewed·Mar 1, 2022
- Conserved Roles for Receptor Tyrosine Kinase Extracellular Regions in Regulating Receptor and Pathway Activity
Mónica González-Magaldi, Jacqueline M. McCabe, … Daniel J. Leahy·Biochemical JournalPeer-reviewed·Oct 12, 2020
- On a mechanistic impact of transmembrane tetramerization in pathological activation of RTKs
A. A. Polyansky, R. G. Efremov·bioRxiv·Oct 14, 2022